Plasma cysteine concentrations in infants with respiratory distress.
Because factors that predispose infants to persistent pulmonary hypertension of the newborn (PPHN) may cause oxidant stress, which in turn may increase demands for cysteine and glutathione, we investigated the availability of cysteine and its precursors in PPHN and related disorders. Plasma concentrations of four sulfur-containing and two non-sulfur-containing amino acids were measured by gas chromatography-mass spectrometry in blood from infants with PPHN, both those managed conventionally (PPHN group) and those treated with extracorporeal membrane oxygenation, as well as from infants with hyaline membrane disease. Concentrations also were measured in umbilical venous cord blood samples from a healthy control population, in venous plasma from infants receiving only intravenously administered glucose-containing solutions because they had noncardiopulmonary illnesses ("fasted" group), and from otherwise healthy, orally fed infants ("fed" group). The plasma total cyst(e)ine concentration was markedly lower in the three groups (PPHN, PPHN and extracorpeal membrane oxygenation, and hyaline membrane disease) receiving an elevated inspired oxygen concentration (0.6 to 1.0) than in fasted or fed control infants. In contrast, levels of plasma methionine, the other major sulfur amino acid, were low in the three groups receiving an elevated inspired oxygen concentration, as well as in fasted infants. Glycine and serine, two non-sulfur-containing amino acids, had a pattern similar to that of plasma methionine. Thus infants with PPHN and hyaline membrane disease have low plasma total cyst(e)ine levels, an effect that does not appear to result primarily from nutritional deprivation. We speculate that the role of cysteine in bioactivation of nitric oxide and as a precursor of glutathione may be relevant to the pathogenesis and evolution of PPHN and respiratory distress syndrome. Further studies are needed to determine whether increased demands for cysteine exist in these disorders.
White
C W
CW
Department of Pediatrics, Children's Hospital, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.
Stabler
S P
SP
Allen
R H
RH
Moreland
S
S
Rosenberg
A A
AA
D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003545:Cysteine / Q000097:blood* / Q000187:drug effects; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D008401:Gas Chromatography-Mass Spectrometry; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D006819:Hyaline Membrane Disease / Q000097:blood* / Q000628:therapy; D007231:Infant, Newborn; D008297:Male; D008715:Methionine / Q000097:blood* / Q000187:drug effects; D010289:Parenteral Nutrition, Total / Q000379:methods*; D010547:Persistent Fetal Circulation Syndrome / Q000097:blood* / Q000628:therapy
D015415:Biomarkers; D008715:Methionine; D005947:Glucose; D003545:Cysteine